# US 2020/0399643 A1 · P38 map kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399643 A1
- Document ID: US20200399643A1
- Status: Published application
- Kind: A1
- Application number: 16/902,029
- Filed: 2020-06-15
- Published: 2020-12-24
- Earliest claimed: 2019-06-20
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: John J. Rossi; Sorah Yoon
- Web page: https://patentgrep.com/patent/US20200399643A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/16: Aptamers
- C12Y 207/11024: Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors

## Claims

### Claim 1

A ribonucleic acid having at least 80% sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

### Claim 2 (depends on 2)

The ribonucleic acid of claim 2, having at least 85% sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

### Claim 3 (depends on 3)

The ribonucleic acid of claim 3, having at least 90% sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

### Claim 4 (depends on 4)

The ribonucleic acid of claim 4, having at least 95% sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

### Claim 5 (depends on 5)

The ribonucleic acid of claim 5, comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

### Claim 6 (depends on 1)

The ribonucleic acid of claim 1, wherein the ribonucleic acid is an aptamer that inhibits phosphorylation of a p38γ mitogen-activated protein kinase.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the ribonucleic acid of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the ribonucleic acid of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is breast cancer, prostate cancer, colon cancer, ovarian cancer, bladder cancer, lung cancer, thyroid cancer, or a head and neck squamous cell carcinoma.

### Claim 10 (depends on 8)

The method of claim 8, wherein the cancer is lymphoma.

### Claim 11 (depends on 8)

The method of claim 8, wherein the cancer is cutaneous T-cell lymphoma.

### Claim 12 (depends on 8)

The method of claim 8, wherein the cancer overexpresses p38γ mitogen-activated protein kinase.

### Claim 13 (depends on 1)

A method of suppressing proliferation of a cutaneous T-cell lymphoma cell, the method comprising contacting the cutaneous T-cell lymphoma cell with an effective amount of the ribonucleic acid of claim 1; thereby suppressing proliferation of the cutaneous T-cell lymphoma cell.

### Claim 14 (depends on 1)

A method of suppressing proliferation of a cancer cell that overexpresses p38γ mitogen-activated protein kinase, the method comprising contacting the cancer cell with an effective amount of the ribonucleic acid of claim 1; thereby suppressing proliferation of the cancer cell.

### Claim 15 (depends on 1)

A method of inhibiting phosphorylation of a p38γ mitogen-activated protein kinase, the method comprising contacting the p38γ mitogen-activated protein kinase with an effective amount of the ribonucleic acid of claim 1; thereby inhibiting phosphorylation of p38γ mitogen-activated protein kinase.